New Ray Medicine International Holding Limited released an announcement on 12 October 2026 outlining the composition of its Board of Directors and the membership of its four key Board committees. The Board comprises five members: two Executive Directors—Ms. Wang Qiuqin, who serves concurrently as Chairman and Chief Executive Officer, and Ms. Zhou Wan—and three Independent Non-Executive Directors—Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy, and Mr. Sy Lai Yin, Sunny.

Audit responsibilities are overseen by the Audit Committee, chaired by Ms. Li Sin Ming, Ivy, with Mr. Leung Chi Kin and Mr. Sy Lai Yin, Sunny as members.

Remuneration matters fall under the Remuneration Committee, chaired by Mr. Leung Chi Kin, with Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny serving alongside.

The Nomination Committee is also chaired by Mr. Leung Chi Kin, joined by Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.

Corporate governance oversight is led by the Corporate Governance Committee, chaired by Ms. Wang Qiuqin and supported by Mr. Sy Lai Yin, Sunny and Ms. Zhou Wan.

The disclosure provides stakeholders with an updated view of the company’s governance framework, highlighting a clear separation of executive and independent oversight roles across its committees.